Nabi Biopharmaceuticals begins human testing of novel vaccine to fight nicotine addiction

Rockville, Maryland, June 12, 2002 Nabi Biopharmaceuticals (Nasdaq: NABI) announced today that they have initiated NicVAX™ (Nicotine Conjugate Vaccine) phase I testing in humans. NicVAX is a proprietary and novel investigational vaccine designed to help the body develop antibodies that bind to nicotine and block it from reaching the brain. If shown to be safe and effective in subsequent clinical trials, NicVAX may help millions of people worldwide kick their addiction to cigarettes and tobacco products.

"NicVAX is an entirely new approach to fighting and preventing nicotine addiction," said David J. Gury, Nabi Biopharmaceuticals chairman, president and chief executive officer.

Of the 48 million adult U.S. smokers, about 70 percent, or nearly 34 million people have made at least one attempt to stop, yet only 1.2 million quit permanently, according to the U.S. Centers for Disease Control and Prevention.

"The reason quitting smoking is so difficult is because nicotine is highly addictive," according to Robert Naso, Ph.D., Nabi Biopharmaceuticals senior vice president of quality, regulatory and product development. "When a person smokes, nicotine enters the body and goes straight to the brain, where it generates positive sensations, such as pleasure and relaxation. However, the body does not develop antibodies against nicotine, no matter how much or for how long a person smokes. Based on earlier animal studies, NicVAX is a technology that enables the body to develop antibodies to nicotine. We believe that these antibodies, acting much like a sponge, will soak up the nicotine, preventing it from reaching the brain."

"By reducing the amount of nicotine available to stimulate the brain's pleasure centers, an immunized tobacco user would theoretically receive no positive reinforcement from nicotine use," according to Dr. Naso. In pre-clinical animal studies NicVAX generated antibodies that reduced nicotine levels in the brain by


Page: 1 2

Related biology news :

1. New hydrothermal vents discovered as South Pacific Odyssey research begins
2. DCI donor services begins distribution of tissue implants
3. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
4. Work begins on powering a sustainable future for the UK
5. As autumn approaches, this chickadees brain begins to expand
6. New study begins to unravel fate of toxic pollutants harbored in Arctic waters
7. UCSF begins distributing the first of its two embryonic stem cell lines
8. Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury
9. The pathway to anxiety begins early in life
10. DOE begins international effort to sequence tree genome
11. Montana State University begins major trout and salmonid book collection

Post Your Comments:

(Date:3/29/2019)... ... ... In the development of biosimilars, the broad definition of the similarity concept in ... several manufacturers have been successful and numerous follow-on biologics are approved in the US ... analytical similarity is achieved in biosimilars based on recently approved products in the US. ...
(Date:3/27/2019)... ATLANTA (PRWEB) , ... March 26, 2019 , ... ... firm Greenberg Traurig, LLP , was a panelist at the National Academy of ... at NAS’ Keck Center. Holden, a member of the firm’s award-winning Pharmaceutical, Medical ...
(Date:3/25/2019)... ... March 25, 2019 , ... Researchers have found multiple applications ... it came into use by the scientific community. Keck Graduate Institute (KGI) Assistant ... to combine the power of CRISPR’s nucleic acid targeting with the ultra sensitivity ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... ... March 19, 2019 , ... Bogey was nine years old when he injured both of his ... These ailments caused Bogey to experience problems with his mobility. According to his ... his special spot on the couch. , His owners, devastated at the sight of Bogey ...
(Date:3/19/2019)... SAN JOSE, Calif. (PRWEB) , ... March 19, ... ... provider of multi-GPU deep learning cloud solutions, today announced it has begun offering ... cloud service offerings. Customers can utilize DGX-1, designed to provide the highest performance ...
(Date:3/14/2019)... ... 14, 2019 , ... The growth in the number and complexity of regulations ... Regulatory intelligence (RI) systems are not keeping ... right Insights faster and cheaper. With a diversity of information sources, identifying and analyzing ...
(Date:3/14/2019)... (PRWEB) , ... March 13, 2019 , ... ... its 2019 ISPE Europe Biotechnology Conference , taking place in Brussels, Belgium ... biotechnology best practices, technical and operational solutions, and innovative approaches. , “Biopharmaceuticals ...
Breaking Biology Technology:
Cached News: